This profile was last updated on .
Is this you? Claim your profile.
+ Get 10 Free Contacts a Month
Please agree to the terms and conditions
Chief Executive Officer
none not applicable
Chief Executive Officer and Chief Financial Officer and Chief Operating Officer
Business & Commerce
University of Mary Washington
Masterâ€™s degree MA
Management & Leadership
Immune Response BioPharma Files Amended FDA BLA for Remune - PR.com
"IRBP values NeuroVax north of a billion dollar of annual sales once approved.
We will find a solid partner or raise capital on our own, we don't need GSK which has zer0 experience in multiple sclerosis or auto-immune diseases.
GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor.
We have decided to terminate any collaboration or development with GSK.
City Of Cockburn
Cantor Colburn LLP
C.H. Robinson Worldwide , Inc.
Children , Inc.